Boned-Murillo Ana, Lucea Mª Jesús López-Prats, Muñoz Enrique Alfonso, Vidal-Oliver Lourdes, Boronat Jorge Mataix, Pozo Elena Palacios, Esteban Mª Carmen Desco
La Princesa University Hospital 28006. Madrid, Spain.
Medical Ophthalmology Foundation of V.C. (FOM) 46015. Valencia, Spain.
Photodiagnosis Photodyn Ther. 2025 Oct;55:104711. doi: 10.1016/j.pdpdt.2025.104711. Epub 2025 Jul 11.
We analyze COVID19 pandemia and shortage of verteporfin (Visudyne®) consequences in photodynamic therapy (PDT) treated patients.
A retrospective study was performed in 97 patients treated with PDT last 3 years. We used HALF DOSE PDT for chronic central serous chorioretinopathy (cCSCR) (n = 84) and FULL DOSE for polypoidal choroidal vasculopathy (PCV) (n = 13). We evaluated changes in visual acuity (VA) and resolution of subretinal fluid (SRF) by optical coherence tomography (OCT), assessing the number of retreatments.
The mean referral delay time was 28.5 ± 6.24 months. 53.6 % of cCSCR and 75 % of PCV patients received previous treatments. An improvement in VA was observed in cCSCR patients after treatment, while PCV patients tends to stabilization. Patients with longer therapeutic delay (≥1 year) showed worse VA. Complete resolution of SRF was noted in 71.4 % of cCSCR and 83.3 % of PCV patients. The shorter the referral delay, the better the resolution rate (76.9 % < 1 year vs 61.5 % if ≥1 year). One-third-of patients required retreatment, superior if longer delay (26.9 % if <1 year vs 34.3 % if ≥1 year).
Even with referral delay or chronic evolution, PDT is worth it and safe to resolve SRF or polyps activity for cCSCR and PCV.
我们分析了接受光动力疗法（PDT）治疗的患者中，2019冠状病毒病大流行及维替泊芬（Visudyne®）短缺所带来的影响。
对过去3年接受PDT治疗的97例患者进行了一项回顾性研究。我们对慢性中心性浆液性脉络膜视网膜病变（cCSCR）患者采用半剂量PDT（n = 84），对息肉样脉络膜血管病变（PCV）患者采用全剂量PDT（n = 13）。我们通过光学相干断层扫描（OCT）评估视力（VA）变化和视网膜下液（SRF）的消退情况，并评估再次治疗的次数。
平均转诊延迟时间为28.5±6.24个月。53.6%的cCSCR患者和75%的PCV患者曾接受过治疗。cCSCR患者治疗后视力有所改善，而PCV患者趋于稳定。治疗延迟较长（≥1年）的患者视力较差。71.4%的cCSCR患者和83.3%的PCV患者的SRF完全消退。转诊延迟越短，消退率越高（<1年为76.9%，≥1年为61.5%）。三分之一的患者需要再次治疗，延迟时间越长再次治疗的比例越高（<1年为26.9%，≥1年为34.3%）。
即使存在转诊延迟或病情慢性进展，PDT对于解决cCSCR和PCV的SRF或息肉活性而言，仍是值得且安全的。
